<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006256</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU2199</org_study_id>
    <nct_id>NCT00006256</nct_id>
  </id_info>
  <brief_title>Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining paclitaxel with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This trial is to study the effectiveness of concurrent administration of&#xD;
      chemotherapy and radiation therapy in treating women who have stage II or stage III breast&#xD;
      cancer by examining the complications and cosmetic effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of concurrent paclitaxel and breast radiotherapy in women with&#xD;
           stage II or III breast cancer who have had primary breast conserving surgery and&#xD;
           adjuvant chemotherapy.&#xD;
&#xD;
        -  Assess the cosmetic results of breast conservation after this treatment in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pulmonary toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3&#xD;
      weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.&#xD;
      Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1 month, every 3 months for 1 year, every 6 months for the next 5&#xD;
      years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study over 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 8, 2000</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Actual">November 30, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the feasibility of concurrent paclitaxel and breast radiotherapy</measure>
    <time_frame>Followed every 3 months for 1 year</time_frame>
    <description>Ability to deliver appropriate doses of radiation therapy within the appropriate time course</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chemotherapy dose achieved during concurrent Taxol and radiation therapy.</measure>
    <time_frame>Followed every 3 months for 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome based upon established descriptive parameters: excellent, good, fair, and poor.</measure>
    <time_frame>1 year</time_frame>
    <description>These parameters will be assessed by medical and radiation oncology. We expect at least a &gt; 60% completion rate with this treatment, which translates into confidence limits of 46% to 74% when 40 patients are investigated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>1 year</time_frame>
    <description>Combined treatment impact on pulmonary function. Evidence of pulmonary toxicity demonstrated by a reduction in DLCO (Diffusing Capacity of the Lung for Carbon Monoxide).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Patients followed for long term survival for at least 5 years.</description>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>doxorubicin and cyclophosphamide adjuvant regimen</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Stage II or III invasive breast cancer&#xD;
&#xD;
          -  Prior breast conserving surgery (lumpectomy or quadrantectomy) with ipsilateral&#xD;
             axillary lymph node dissection required&#xD;
&#xD;
          -  No prior contralateral breast cancer&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Prior ductal carcinoma in situ or lobular carcinoma in situ of the breast allowed&#xD;
             unless treated with radiation or chemotherapy&#xD;
&#xD;
          -  Doxorubicin and cyclophosphamide adjuvant chemotherapy completed within past 3 weeks&#xD;
&#xD;
          -  Candidate for definitive radiotherapy&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Granulocyte count at least 2,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT/AST no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No concurrent poorly controlled ischemic heart disease or congestive heart failure&#xD;
&#xD;
          -  LVEF at least 45% by MUGA scan or echocardiogram&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No concurrent severe chronic obstructive or restrictive pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent severe medical or psychiatric illness&#xD;
&#xD;
          -  No concurrent severe diabetes mellitus&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix treated with local excision&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior tamoxifen allowed&#xD;
&#xD;
          -  No concurrent tamoxifen&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiation to the breast&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered form prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent adjuvant therapy on another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Lyons, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH-CantonMercy</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Geauga</name>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <zip>44024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Monarch</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-LUICC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Southwest</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Chagrin Highlands</name>
      <address>
        <city>Orange Village</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Green Road</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Westlake</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 30, 2023</last_update_submitted>
  <last_update_submitted_qc>January 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

